Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15443

    +

    P3.04-061 - Thoracic Oncology Clinic: Our First 200 Cases, San Jose, Costa Rica (ID 275)

    09:30 - 09:30  |  Author(s): R. Rojas Vigott
    • Abstract

    Background:
    Lung Cancer has been gaining interest in our country, because there is a higher number of cases and the capacity to make diagnosis and give opportunities of treatment t the patiens. As we give opportunities of treatment to th patients.As we realized, this is a complex pathology, and heterogeneous disease. For that reason, we decided three years ago, to orgnize a multidisciplinary approach for lung cancer patients and to obtain our own statistis.
    
    Methods:
    We reviewed 200 cases (files) and followed the patients during the last 3 years. (Retrospective study)
    
    Results:
    We attended 200 cases with teh diagnosis of lung cancer. The average age was 63 years old. 62% of patients were female. 68% patients had an adenocarcinoma histology, 17% squamus cell and 10% Small Cell Lung cancer. 59% of patients were people who used to smoke, 41% never smoke. 69% were patients inn stage IV disease, 16% stage III (A,B) and 15% Stage I. From patients in stage IV, 73% received some medical treatment. We tested 100 patients who hat adenocarcinoma for EGFR mutation. 26% of the patients with adenocarcinoma had EGFR (+) ; 53% exon 19, 7% exon 20 and 34% exon 21. 9 patients have received treatment with Erlotinib. 6 of them have accomplished al least 10 months of PFS, and least 1.5 years of OS.
    
    Conclusion:
    We understand taht lung cancer is a complex disease and we are getting our first results of the multidisciplinary work in our hospital. We are so motivated to continue working in this paticular cancer and to understand the profile of our patients. The majority of our patients are in stage IV, nevertheless tha major part of them have the opportunity to receive some medical treatment. Testing for EGFR is now a routine exam, and the analisys of new targets (ALK) is our concern.In Costa Rica the incidence of EGFR positive is around 26%. We are analizing actual data in relation to OS and PFS.